Short sleepers cruise by on four to six hours a night and don’t seem to suffer ill effects. Turns out they’re genetically ...

Problems with sleep likely develop before motor symptoms in people with amyotrophic lateral sclerosis, a new study shows.

Amyotrophic lateral sclerosis (ALS), also known as Charcot’s disease, or Lou Gehrig’s disease, is a severe neurodegenerative ...

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, ...

In a recent transaction, Allen S. Melemed, the Chief Medical (TASE:PMCN) Officer of Chimerix Inc . (NASDAQ:CMRX), sold 3,065 shares of the company's common stock. The shares were sold at an average ...

QUVIVIQ™ is a novel dual orexin receptor agonist that was successfully developed through a Phase 3 trial by Nxera Pharma Japan (“NPJ,” a wholly owned subsidiary of Nxera Pharma). QUVIVIQ™ was launched ...

Goldman Sachs raised the firm’s price target on Alkermes (ALKS) to $32 from $30 and keeps a Buy rating on the shares after its Q4 earnings beat ...

For 2025, Alkermes plans to generate over $200 million in EBITDA while advancing its orexin program, particularly ALKS 2680, which is enrolling Phase 2 studies for narcolepsy. These studies are ...

Deutsche Bank (ETR:DBKGn) initiated coverage on Alkermes (NASDAQ:ALKS) shares with a Buy rating and a price target of $40.00.